Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of the tottering mouse.
Samuel W Cramer, Laurentiu S Popa, Russell E Carter, Gang Chen, Timothy J Ebner
Index: J. Neurosci. 35(14) , 5664-79, (2015)
Full Text: HTML
Abstract
The Ca(2+) channelopathies caused by mutations of the CACNA1A gene that encodes the pore-forming subunit of the human Cav2.1 (P/Q-type) voltage-gated Ca(2+) channel include episodic ataxia type 2 (EA2). Although, in EA2 the emphasis has been on cerebellar dysfunction, patients also exhibit episodic, nonmotoric abnormalities involving the cerebral cortex. This study demonstrates episodic, low-frequency oscillations (LFOs) throughout the cerebral cortex of tottering (tg/tg) mice, a widely used model of EA2. Ranging between 0.035 and 0.11 Hz, the LFOs in tg/tg mice can spontaneously develop very high power, referred to as a high-power state. The LFOs in tg/tg mice are mediated in part by neuronal activity as tetrodotoxin decreases the oscillations and cortical neuron discharge contain the same low frequencies. The high-power state involves compensatory mechanisms because acutely decreasing P/Q-type Ca(2+) channel function in either wild-type (WT) or tg/tg mice does not induce the high-power state. In contrast, blocking l-type Ca(2+) channels, known to be upregulated in tg/tg mice, reduces the high-power state. Intriguingly, basal excitatory glutamatergic neurotransmission constrains the high-power state because blocking ionotropic or metabotropic glutamate receptors results in high-power LFOs in tg/tg but not WT mice. The high-power LFOs are decreased markedly by acetazolamide and 4-aminopyridine, the primary treatments for EA2, suggesting disease relevance. Together, these results demonstrate that the high-power LFOs in the tg/tg cerebral cortex represent a highly abnormal excitability state that may underlie noncerebellar symptoms that characterize CACNA1A mutations. Copyright © 2015 the authors 0270-6474/15/355664-16$15.00/0.
Related Compounds
Related Articles:
2015-01-01
[J. Biochem. 157(1) , 53-64, (2015)]
2011-01-15
[Bioorg. Med. Chem. Lett. 21 , 710-4, (2011)]
2014-11-14
[J. Chromatogr. A. 1368 , 44-51, (2014)]
2014-12-01
[J. Enzyme Inhib. Med. Chem. 29(6) , 846-67, (2014)]
2015-02-01
[Metab. Brain Dis. 30(1) , 47-55, (2015)]